Aktie A40AZJ RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Rapid Therapeutic Science Laboratories, Inc.

Aktien

A40AZJ

US7534312043

RTSL

Markt geschlossen - OTC Markets
Andere Börsenplätze
 17:09:20 10.04.2024 		% 5 Tage % 1. Jan.
0,005 USD +25,00 % Intraday Chart für Rapid Therapeutic Science Laboratories, Inc. 0,00 % +21,95 %
2023 Rapid Therapeutic Science Laboratories, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023 CI
2023 Rapid Therapeutic Science Laboratories, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt
White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy
Rapid Therapeutic Science Laboratories Updates Patents
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A40AZJ Aktie
  4. Nachrichten Rapid Therapeutic Science Laboratories, Inc.
  5. Andere Sprachen